Results from field trials undertaken during 2013 and 2014

The trial in 2013 was a commercial trial with a customer in Central Norway with v12G, where two sets of two cages were compared with respect to origin and disease history. The trial in 2014 was carried out on a group of fish in southern Norway without significant disease problems during the trial period.

Field trial, 2013

During this trial, two sets of two cages were compared with respect to origin and disease history.

• (Two control cages + two trial cages with equal groups of fish).
• HSMI was evident in all the groups, but with more extensive symptoms in two of the cages. 
• Incipient clinical CMS was detected in one pair of cages (1 Qardio and 1 control). 
• Analyses were focused on measuring the effects on disease progression.

All histological assessments were conducted by Øystein Evensen of the NMBU Faculty of Veterinary Medicine.

The diagram shows the development in cumulative mortality throughout the trial. In both cage pairs, a gradually increasing difference between the trials cage and the control cage was observed. The Qardio group displayed a consistently lower mortality rate throughout the experiment in both pairs.

The trial group displayed via histological evaluation at the time of slaughter, a consistently lower level of damage to the cardiac musculature in both cage pairs. 

Field trial, 2014

This trial (2 + 2 set up, 2014) was carried out in southern Norway on a group of fish with no significant disease problems during the trials period. Sampling and analysis was therefore focused on measuring differences in biometrics.

The trial group had higher average relative heart weights than the control group in both cage pairs. The difference was statistically significant in one of the two cage pairs.